Medicure Inc. Logo

Medicure Inc.

MCUJF

(2.0)
Stock Price

0,65 USD

-15.95% ROA

-10.18% ROE

-3.68x PER

Market Cap.

9.691.160,70 USD

2.06% DER

0% Yield

-9.65% NPM

Medicure Inc. Stock Analysis

Medicure Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medicure Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 PBV

With a remarkably low PBV ratio (0.65x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (4%), which means it has a small amount of debt compared to the ownership it holds

4 ROE

ROE in an average range (8.8%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Medicure Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medicure Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Medicure Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medicure Inc. Revenue
Year Revenue Growth
2001 135.868
2002 183.912 26.12%
2003 241.281 23.78%
2004 445.461 45.84%
2005 459.197 2.99%
2006 299.737 -53.2%
2007 5.944.730 94.96%
2008 2.247.129 -164.55%
2009 4.792.513 53.11%
2010 3.317.073 -44.48%
2011 3.628.274 8.58%
2012 4.796.811 24.36%
2013 2.602.700 -84.3%
2014 5.050.761 48.47%
2015 22.083.128 77.13%
2016 37.778.471 41.55%
2017 27.132.832 -39.24%
2018 29.109.365 6.79%
2019 20.173.000 -44.3%
2020 11.610.000 -73.76%
2021 21.744.000 46.61%
2022 23.065.000 5.73%
2023 20.008.000 -15.28%
2023 21.694.000 7.77%
2024 20.660.000 -5%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medicure Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2001 2.475.387
2002 3.048.925 18.81%
2003 3.117.619 2.2%
2004 4.278.667 27.14%
2005 13.564.068 68.46%
2006 10.219.026 -32.73%
2007 23.335.752 56.21%
2008 28.660.250 18.58%
2009 22.706 -126123.24%
2010 393.385 94.23%
2011 204.690 -92.19%
2012 1.044.491 80.4%
2013 1.700.479 38.58%
2014 688.671 -146.92%
2015 4.865.255 85.85%
2016 5.092.495 4.46%
2017 5.148.233 1.08%
2018 6.681.013 22.94%
2019 4.349.000 -53.62%
2020 3.299.000 -31.83%
2021 1.796.000 -83.69%
2022 2.754.000 34.79%
2023 2.032.000 -35.53%
2023 2.406.000 15.54%
2024 3.472.000 30.7%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medicure Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 3.353.000 100%
2018 19.502.337 82.81%
2019 3.395.000 -474.44%
2020 4.579.000 25.86%
2021 2.697.000 -69.78%
2022 4.193.000 35.68%
2023 4.096.000 -2.37%
2023 4.131.000 0.85%
2024 5.472.000 24.51%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medicure Inc. EBITDA
Year EBITDA Growth
2001 -3.214.561
2002 -3.814.582 15.73%
2003 -4.160.563 8.32%
2004 -5.948.080 30.05%
2005 -15.361.370 61.28%
2006 -12.577.295 -22.14%
2007 -28.395.030 55.71%
2008 -25.786.503 -10.12%
2009 -904.993 -2749.36%
2010 -2.293.670 60.54%
2011 -67.624 -3291.8%
2012 887.641 107.62%
2013 -1.622.270 154.72%
2014 -623.645 -160.13%
2015 1.620.542 138.48%
2016 6.793.032 76.14%
2017 11.837.027 42.61%
2018 -1.339.106 983.95%
2019 -8.805.000 84.79%
2020 -4.514.000 -95.06%
2021 2.571.000 275.57%
2022 3.365.000 23.6%
2023 432.000 -678.94%
2023 1.316.000 67.17%
2024 -2.224.000 159.17%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medicure Inc. Gross Profit
Year Gross Profit Growth
2001 135.868
2002 183.912 26.12%
2003 241.281 23.78%
2004 445.461 45.84%
2005 459.197 2.99%
2006 299.737 -53.2%
2007 5.556.927 94.61%
2008 1.641.506 -238.53%
2009 4.415.434 62.82%
2010 2.745.385 -60.83%
2011 2.954.752 7.09%
2012 3.727.532 20.73%
2013 1.936.804 -92.46%
2014 4.182.639 53.69%
2015 19.823.261 78.9%
2016 28.009.206 29.23%
2017 23.668.146 -18.34%
2018 24.957.127 5.16%
2019 12.901.000 -93.45%
2020 5.130.000 -151.48%
2021 12.712.000 59.64%
2022 16.075.000 20.92%
2023 14.560.000 -10.41%
2023 13.555.001 -7.41%
2024 11.808.000 -14.8%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medicure Inc. Net Profit
Year Net Profit Growth
2001 -3.232.010
2002 -3.875.087 16.6%
2003 -4.193.688 7.6%
2004 -5.989.086 29.98%
2005 -14.865.910 59.71%
2006 -12.607.074 -17.92%
2007 -31.703.386 60.23%
2008 -57.402.521 44.77%
2009 -13.315.827 -331.08%
2010 -5.532.506 -140.68%
2011 -2.014.109 -174.69%
2012 23.385.779 108.61%
2013 -2.574.304 1008.43%
2014 -1.638.952 -57.07%
2015 1.668.429 198.23%
2016 27.657.474 93.97%
2017 43.420.884 36.3%
2018 3.925.639 -1006.08%
2019 -19.786.000 119.84%
2020 -6.894.000 -187%
2021 -727.000 -848.28%
2022 1.365.000 153.26%
2023 336.000 -306.25%
2023 -922.000 136.44%
2024 -4.868.000 81.06%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medicure Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 -3
2002 -2 -50%
2003 -2 -100%
2004 -2 0%
2005 -3 66.67%
2006 -3 -50%
2007 -5 50%
2008 -7 33.33%
2009 -2 -500%
2010 -1 0%
2011 0 0%
2012 2 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 2 100%
2017 3 50%
2018 0 0%
2019 -1 100%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medicure Inc. Free Cashflow
Year Free Cashflow Growth
2001 -2.864.253
2002 -4.205.745 31.9%
2003 -3.988.431 -5.45%
2004 -6.173.938 35.4%
2005 -12.110.311 49.02%
2006 -13.922.393 13.02%
2007 -25.433.698 45.26%
2008 -41.879.228 39.27%
2009 -10.656.681 -292.99%
2010 -1.594.640 -568.28%
2011 432.665 468.56%
2012 319.377 -35.47%
2013 -997.875 132.01%
2014 105.367 1047.05%
2015 -83.775 225.77%
2016 5.946.603 101.41%
2017 20.601.285 71.13%
2018 -735.761 2900%
2019 -28.487.000 97.42%
2020 -2.242.000 -1170.61%
2021 3.171.000 170.7%
2022 1.518.000 -108.89%
2023 146.000 -939.73%
2023 1.809.000 91.93%
2024 -134.000 1450%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medicure Inc. Operating Cashflow
Year Operating Cashflow Growth
2001 -2.729.996
2002 -4.167.757 34.5%
2003 -3.983.235 -4.63%
2004 -6.152.208 35.26%
2005 -12.067.515 49.02%
2006 -12.678.498 4.82%
2007 -25.246.653 49.78%
2008 -41.864.640 39.69%
2009 -10.418.139 -301.84%
2010 -1.452.809 -617.1%
2011 477.479 404.27%
2012 417.289 -14.42%
2013 -990.478 142.13%
2014 110.880 993.29%
2015 142.795 22.35%
2016 6.410.811 97.77%
2017 21.923.132 70.76%
2018 742.273 -2853.51%
2019 -14.641.000 105.07%
2020 -2.240.000 -553.62%
2021 3.989.000 156.15%
2022 1.828.000 -118.22%
2023 173.000 -956.65%
2023 2.079.000 91.68%
2024 -30.000 7030%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medicure Inc. Capital Expenditure
Year Capital Expenditure Growth
2001 134.257
2002 37.988 -253.42%
2003 5.196 -631.1%
2004 21.730 76.09%
2005 42.796 49.22%
2006 1.243.895 96.56%
2007 187.045 -565.02%
2008 14.588 -1182.18%
2009 238.542 93.88%
2010 141.831 -68.19%
2011 44.814 -216.49%
2012 97.912 54.23%
2013 7.397 -1223.67%
2014 5.513 -34.17%
2015 226.570 97.57%
2016 464.208 51.19%
2017 1.321.847 64.88%
2018 1.478.034 10.57%
2019 13.846.000 89.33%
2020 2.000 -692200%
2021 818.000 99.76%
2022 310.000 -163.87%
2023 27.000 -1048.15%
2023 270.000 90%
2024 104.000 -159.62%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medicure Inc. Equity
Year Equity Growth
2001 3.851.963
2002 8.987.128 57.14%
2003 4.942.100 -81.85%
2004 21.568.138 77.09%
2005 7.340.105 -193.84%
2006 37.169.738 80.25%
2007 34.306.469 -8.35%
2008 -6.556.160 623.27%
2009 -19.546.959 66.46%
2010 -24.956.653 21.68%
2011 -26.893.705 7.2%
2012 -1.820.673 -1377.13%
2013 -4.326.681 57.92%
2013 -4.326.681 0%
2014 -3.911.016 -10.63%
2015 4.461.551 187.66%
2016 38.958.737 88.55%
2017 80.709.160 51.73%
2018 83.593.545 3.45%
2019 26.942.000 -210.27%
2020 19.146.000 -40.72%
2021 18.411.000 -3.99%
2022 21.005.000 12.35%
2023 19.896.000 -5.57%
2023 21.866.000 9.01%
2024 19.541.000 -11.9%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medicure Inc. Assets
Year Assets Growth
2001 4.422.040
2002 9.376.791 52.84%
2003 5.296.008 -77.05%
2004 22.385.712 76.34%
2005 10.072.859 -122.24%
2006 38.814.077 74.05%
2007 59.785.803 35.08%
2008 34.805.233 -71.77%
2009 9.549.960 -264.45%
2010 5.973.074 -59.88%
2011 5.173.907 -15.45%
2012 4.743.624 -9.07%
2013 3.423.789 -38.55%
2013 3.423.789 0%
2014 6.560.519 47.81%
2015 21.256.878 69.14%
2016 214.725.667 90.1%
2017 128.931.685 -66.54%
2018 103.761.413 -24.26%
2019 42.284.000 -145.39%
2020 34.054.000 -24.17%
2021 28.408.000 -19.87%
2022 29.898.000 4.98%
2023 28.059.000 -6.55%
2023 28.845.000 2.72%
2024 28.236.000 -2.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medicure Inc. Liabilities
Year Liabilities Growth
2001 570.077
2002 389.663 -46.3%
2003 353.908 -10.1%
2004 817.574 56.71%
2005 2.732.754 70.08%
2006 1.644.339 -66.19%
2007 25.479.334 93.55%
2008 41.361.393 38.4%
2009 29.096.919 -42.15%
2010 30.929.727 5.93%
2011 32.067.612 3.55%
2012 6.564.297 -388.52%
2013 7.750.470 15.3%
2013 7.750.470 0%
2014 10.471.535 25.99%
2015 16.795.327 37.65%
2016 175.766.930 90.44%
2017 48.222.525 -264.49%
2018 20.167.868 -139.11%
2019 15.342.000 -31.46%
2020 14.908.000 -2.91%
2021 9.997.000 -49.12%
2022 8.893.000 -12.41%
2023 8.163.000 -8.94%
2023 6.979.000 -16.97%
2024 8.695.000 19.74%

Medicure Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.01
Net Income per Share
-0.25
Price to Earning Ratio
-3.68x
Price To Sales Ratio
0.46x
POCF Ratio
8.42
PFCF Ratio
13.52
Price to Book Ratio
0.5
EV to Sales
0.2
EV Over EBITDA
-4.66
EV to Operating CashFlow
3.69
EV to FreeCashFlow
5.92
Earnings Yield
-0.27
FreeCashFlow Yield
0.07
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
3.26
Graham NetNet
0.23

Income Statement Metrics

Net Income per Share
-0.25
Income Quality
-0.44
ROE
-0.13
Return On Assets
-0.07
Return On Capital Employed
-0.19
Net Income per EBT
1.05
EBT Per Ebit
0.51
Ebit per Revenue
-0.18
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
0.22
Research & Developement to Revenue
0.13
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.56
Operating Profit Margin
-0.18
Pretax Profit Margin
-0.09
Net Profit Margin
-0.1

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.11
Free CashFlow per Share
0.07
Capex to Operating CashFlow
0.38
Capex to Revenue
0.02
Capex to Depreciation
0.2
Return on Invested Capital
-0.13
Return on Tangible Assets
-0.16
Days Sales Outstanding
78.08
Days Payables Outstanding
364.96
Days of Inventory on Hand
170
Receivables Turnover
4.67
Payables Turnover
1
Inventory Turnover
2.15
Capex per Share
0.04

Balance Sheet

Cash per Share
0,56
Book Value per Share
1,87
Tangible Book Value per Share
0.75
Shareholders Equity per Share
1.87
Interest Debt per Share
0.04
Debt to Equity
0.02
Debt to Assets
0.01
Net Debt to EBITDA
5.99
Current Ratio
1.87
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
19650000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.42
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
3569000
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medicure Inc. Dividends
Year Dividends Growth

Medicure Inc. Profile

About Medicure Inc.

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

CEO
Dr. Albert David Friesen Ph.D.
Employee
0
Address
2-1250 Waverley Street
Winnipeg, R3T 6C6

Medicure Inc. Executives & BODs

Medicure Inc. Executives & BODs
# Name Age
1 Dr. Albert David Friesen Ph.D.
Founder, Chief Executive Officer & Chairman of the board
70
2 Mr. Haaris Uddin B.Com., CPA
Chief Financial Officer
70
3 Dr. Reuben Saba Ph.D.
Vice President of Scientific & Medical Affairs
70
4 Dr. Neil Owens Ph.D.
President & Chief Operating Officer
70

Medicure Inc. Competitors